High expression levels of egfl7 correlate with low endothelial cell activation in peritumoral vessels of human breast cancer

Pannier,Diane; Philippin‑Lauridant,Géraldine; Baranzelli,Marie‑Christine; Bertin,Delphine; Bogart,Emilie; Delprat,Victor; Villain,Gaëlle; Mattot,Virginie; Bonneterre,Jacques; Soncin,Fabrice

doi:10.3892/ol.2016.4791

High expression levels of egfl7 correlate with low endothelial cell activation in peritumoral vessels of human breast cancer

Authors:
- Diane Pannier
- Géraldine Philippin‑Lauridant
- Marie‑Christine Baranzelli
- Delphine Bertin
- Emilie Bogart
- Victor Delprat
- Gaëlle Villain
- Virginie Mattot
- Jacques Bonneterre
- Fabrice Soncin
View Affiliations

Affiliations: Senology Department, Oscar Lambret Center, Université de Lille, 59020 Lille, France, Institut Pasteur de Lille, Centre National de la Recherche Scientifique UMR8161, Université de Lille, 59000 Lille, France
Published online on: June 28, 2016 https://doi.org/10.3892/ol.2016.4791
Pages: 1422-1428
Copyright: © Pannier et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Tumor blood vessels participate in the immune response against cancer cells and we previously used pre-clinical models to demonstrate that egfl7 (VE‑statin) promotes tumor cell evasion from the immune system by repressing endothelial cell activation, preventing immune cells from entering the tumor mass. In the present study, the expression levels of egfl7 and that of ICAM‑1 as a marker of endothelium activation, were evaluated in peritumoral vessels of human breast cancer samples. Breast cancer samples (174 invasive and 30 in situ) from 204 patients treated in 2005 were immunostained for CD31, ICAM‑1 and stained for egfl7 using in situ hybridization. The expression levels of ICAM‑1 and egfl7 were assessed in peritumoral areas using semi‑quantitative scales. There was a strong and significant inverse correlation between the expression of ICAM‑1 and that of egfl7 in CD31+ blood vessels. When the ICAM‑1 score increased, the egfl7 score reduced significantly (P=0.004), and vice‑versa (Cuzick's test for trend across ordered groups). In order to determine which gene influenced the other gene between egfl7 and ICAM‑1, the expression levels of either gene were modulated in endothelial cells. Egfl7 regulated ICAM‑1 expression while ICAM‑1 had no effects on egfl7 expression in the same conditions. Altogether, these results provide further results that egfl7 serves a regulatory role in endothelial cell activation in relation to immune infiltration and that it is a potential therapeutic target to consider for improving anticancer immunotherapies.

View Figures

View References

1	Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
2	Chen DS and Mellman I: Oncology meets immunology: The cancer-immunity cycle. Immunity. 39:1–10. 2013. View Article : Google Scholar : PubMed/NCBI
3	Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 366:2443–2454. 2012. View Article : Google Scholar : PubMed/NCBI
4	Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, et al: Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 373:123–135. 2015. View Article : Google Scholar : PubMed/NCBI
5	Muller WA: Mechanisms of transendothelial migration of leukocytes. Circ Res. 105:223–230. 2009. View Article : Google Scholar : PubMed/NCBI
6	Herberman RB, Nunn ME, Holden HT and Lavrin DH: Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. II. Characterization of effector cells. Int J Cancer. 16:230–239. 1975. View Article : Google Scholar : PubMed/NCBI
7	Shrikant P and Mescher MF: Control of syngeneic tumor growth by activation of CD8+ T cells: Efficacy is limited by migration away from the site and induction of nonresponsiveness. J Immunol. 162:2858–2866. 1999.PubMed/NCBI
8	Soncin F, Mattot V, Lionneton F, Spruyt N, Lepretre F, Begue A and Stehelin D: VE-statin, an endothelial repressor of smooth muscle cell migration. Embo J. 22:5700–5711. 2003. View Article : Google Scholar : PubMed/NCBI
9	Parker LH, Schmidt M, Jin SW, Gray AM, Beis D, Pham T, Frantz G, Palmieri S, Hillan K, Stainier DY, et al: The endothelial-cell-derived secreted factor Egfl7 regulates vascular tube formation. Nature. 428:754–758. 2004. View Article : Google Scholar : PubMed/NCBI
10	Fitch MJ, Campagnolo L, Kuhnert F and Stuhlmann H: Egfl7, a novel epidermal growth factor-domain gene expressed in endothelial cells. Dev Dyn. 230:316–324. 2004. View Article : Google Scholar : PubMed/NCBI
11	Diaz R, Silva J, Garcia JM, Lorenzo Y, García V, Peña C, Rodríguez R, Muñoz C, García F, Bonilla F and Domínguez G: Deregulated expression of miR-106a predicts survival in human colon cancer patients. Genes Chromosomes Cancer. 47:794–802. 2008. View Article : Google Scholar : PubMed/NCBI
12	Wu F, Yang LY, Li YF, Ou DP, Chen DP and Fan C: Novel role for epidermal growth factor-like domain 7 in metastasis of human hepatocellular carcinoma. Hepatology. 50:1839–1850. 2009. View Article : Google Scholar : PubMed/NCBI
13	Huang CH, Li XJ, Zhou YZ, Luo Y, Li C and Yuan XR: Expression and clinical significance of Egfl7 in malignant glioma. J Cancer Res Clin Oncol. 136:1737–1743. 2010. View Article : Google Scholar : PubMed/NCBI
14	Zhou L, Li J, Zhao YP, Guo JC, Cui QC, Zhou WX, Zhang TP, Wu WM, You L and Shu H: Prognostic significance of epidermal growth factor-like domain 7 in pancreatic cancer. Hepatobiliary Pancreat Dis. 13:523–528. 2014. View Article : Google Scholar
15	Delfortrie S, Pinte S, Mattot V, Samson C, Villain G, Caetano B, Lauridant-Philippin G, Baranzelli MC, Bonneterre J, Trottein F, et al: Egfl7 promotes tumor escape from immunity by repressing endothelial cell activation. Cancer Res. 71:7176–7186. 2011. View Article : Google Scholar : PubMed/NCBI
16	Lelièvre E, Hinek A, Lupu F, Buquet C, Soncin F and Mattot V: VE-statin/egfl7 regulates vascular elastogenesis by interacting with lysyl oxidases. Embo J. 27:1658–1670. 2008.Can't. View Article : Google Scholar : PubMed/NCBI
17	Miettinen M: Immunohistochemistry of soft tissue tumours - review with emphasis on 10 markers. Histopathology. 64:101–118. 2014. View Article : Google Scholar : PubMed/NCBI
18	Penault-Llorca F and Arnould L: Adjuvant breast cancer: Which clinical and pathological characteristics in 2007? Bull Cancer. 97:1421–1426. 2010.(In French). PubMed/NCBI
19	Fina L, Molgaard HV, Robertson D, Bradley NJ, Monaghan P, Delia D, Sutherland DR, Baker MA and Greaves MF: Expression of the CD34 gene in vascular endothelial cells. Blood. 75:2417–2426. 1990.PubMed/NCBI
20	Schröder C, Witzel I, Müller V, Krenkel S, Wirtz RM, Jänicke F, Schumacher U and Milde-Langosch K: Prognostic value of intercellular adhesion molecule (ICAM)-1 expression in breast cancer. J Cancer Res Clin Oncol. 137:1193–1201. 2011. View Article : Google Scholar : PubMed/NCBI
21	Fox SB, Turner GD, Leek RD, Whitehouse RM, Gatter KC and Harris AL: The prognostic value of quantitative angiogenesis in breast cancer and role of adhesion molecule expression in tumor endothelium. Breast Cancer Res Treat. 36:219–226. 1995. View Article : Google Scholar : PubMed/NCBI
22	Bouma-ter Steege JC, Baeten CIM, Thijssen VL, Satijn SA, Verhoeven IC, Hillen HF, Wagstaff J and Griffioen AW: Angiogenic profile of breast carcinoma determines leukocyte infiltration. Clin Cancer Res. 10:7171–7178. 2004. View Article : Google Scholar : PubMed/NCBI
23	Guo P, Huang J, Wang L, Jia D, Yang J, Dillon DA, Zurakowski D, Mao H, Moses MA and Auguste DT: ICAM-1 as a molecular target for triple negative breast cancer. Proc Natl Acad Sci USA. 111:14710–14715. 2014. View Article : Google Scholar : PubMed/NCBI
24	Philippin-Lauridant G, Baranzelli M-C, Samson C, Fournier C, Pinte S, Mattot V, Bonneterre J and Soncin F: Expression of Egfl7 correlates with low-grade invasive lesions in human breast cancer. Int J Oncol. 42:1367–1375. 2013.PubMed/NCBI
25	Rao VN, Huebner K, Isobe M, Ar RA, Croce CM and Reddy ES: elk, tissue-specific ets-related genes on chromosomes X and 14 near translocation breakpoints. Science. 244:66–70. 1989. View Article : Google Scholar : PubMed/NCBI
26	Kuldo JM, Westra J, Asgeirsdóttir SA, Kok RJ, Oosterhuis K, Rots MG, Schouten JP, Limburg PC and Molema G: Differential effects of NF-{kappa}B and p38 MAPK inhibitors and combinations thereof on TNF-{alpha}- and IL-1{beta}-induced proinflammatory status of endothelial cells in vitro. Am J Physiol Cell Physiol. 289:C1229–C1239. 2005. View Article : Google Scholar : PubMed/NCBI
27	Maeng YS, Min JK, Kim JH, Yamagishi A, Mochizuki N, Kwon JY, Park YW, Kim YM and Kwon YG: ERK is an anti-inflammatory signal that suppresses expression of NF-kappaB-dependent inflammatory genes by inhibiting IKK activity in endothelial cells. Cell Signal. 18:994–1005. 2006. View Article : Google Scholar : PubMed/NCBI
28	Zhou Z, Connell MC and MacEwan DJ: TNFR1-induced NF-kappaB, but not ERK, p38MAPK or JNK activation, mediates TNF-induced ICAM-1 and VCAM-1 expression on endothelial cells. Cell Signal. 19:1238–1248. 2007. View Article : Google Scholar : PubMed/NCBI
29	Badiwala MV, Guha D, Tumiati L, Joseph J, Ghashghai A, Ross HJ, Delgado DH and Rao V: Epidermal growth factor-like domain 7 is a novel inhibitor of neutrophil adhesion to coronary artery endothelial cells injured by calcineurin inhibition. Circulation. 124(11 Suppl): S197–S203. 2011. View Article : Google Scholar : PubMed/NCBI
30	Johnson L, Huseni M, Smyczek T, Lima A, Yeung S, Cheng JH, Molina R, Kan D, De Mazière A, Klumperman J, et al: Anti-Egfl7 antibodies enhance stress-induced endothelial cell death and anti-VEGF efficacy. J Clin Invest. 123:3997–4009. 2013. View Article : Google Scholar : PubMed/NCBI